RUNX1 and acute myeloid leukemia: RUNX1 mutated AML patients have a particularly poor prognosis [22,23] with significantly lower rates of complete remission (47%) and 5-year survival (2%) [22], as compared with those without RUNX1 mutation (77% and 30%, respectively).